"MetCool ACS"- Metformin "Cooling" Effect on metformin-naive Patients Treated with PCI because of Acute Coronary Syndrome
Key facts
- Where
- Bielsk Podlaski, Bielsko-Biala, Chorzow, Chrzanów, Czestochowa, Dąbrowa Górnicza, Ełk, Gdansk, Gorzów Wlkp, Iława, Kluczbork, Krakow, Kraśnik, Kutno, Legionowo, Mrągowo, Poznan, Pulawy, Racibórz, Sieradz, Sosnowiec, Szczecinek, Tomaszów Mazowiecki, Tychy, Warsaw és Zgierz, LengyelországSee the 26 sites
- Phase
- 3. fázis
Where in Lengyelország
- Centrum Kardiologii Scanmed w Bielsku PodlaskimBielsk Podlaski, LengyelországTaking people
- American Heart of Poland S.A.Bielsko-Biala, LengyelországTaking people
- Scanmed S.A.Chorzow, LengyelországTaking people
- Małopolskie Centrum Sercowo-Naczyniowe AhoPChrzanów, LengyelországTaking people
- Scanmed S.A.Czestochowa, LengyelországTaking people
- American Heart of Poland S.A.Dąbrowa Górnicza, LengyelországTaking people
- Centrum Kardiologii Scanmed w EłkuEłk, LengyelországTaking people
- Uniwersyteckie Centrum KliniczneGdansk, LengyelországTaking people
- Wielospecjalistyczny Szpital Wojewódzki w Gorzowie Wlkp. Spółka z Ograniczoną OdpowiedzialnościąGorzów Wlkp, LengyelországTaking people
- Centrum Kardiologii Scanmed w IławieIława, LengyelországTaking people
- Scanmed S.A.Kluczbork, LengyelországTaking people
- Szpital sw. Rafala Scanmed SAKrakow, LengyelországTaking people
- 4Cardia Szpital Kardiologii Inwazyjnej z Oddziałem Chirurgii NaczyniowejKraśnik, LengyelországTaking people
- Scanmed S.A.Kutno, LengyelországTaking people
- Wojskowy Instytut Medyczny - Szpital w LegionowieLegionowo, LengyelországTaking people
- NZOZ Pomorskie Centra KardiologiczneMrągowo, LengyelországTaking people
- Uniwersytecki Szpital Kliniczny w PoznaniuPoznan, LengyelországTaking people
- Samodzielny Publiczny Zaklad Opieki Zdrowotnej W PulawachPulawy, LengyelországTaking people
- Centrum Kardiologii Scanmed w RaciborzuRacibórz, LengyelországTaking people
- Szpital Wojewódzki im. Prymasa Kardynała Stefana Wyszyńskiego w SieradzuSieradz, LengyelországTaking people
- Centrum Kardiologii Scanmed w SosnowcuSosnowiec, LengyelországTaking people
- Centrum Kardiologii Scanmed w SzczecinkuSzczecinek, LengyelországTaking people
- Centrum Kardiologii Scanmed w Tomaszowie MazowieckimTomaszów Mazowiecki, LengyelországTaking people
- American Heart of Poland S.A.Tychy, LengyelországTaking people
- Wojskowy Instytut Medyczny Panstwowy Instytut BadawczyWarsaw, LengyelországTaking people
- American Heart of Poland S.A.Zgierz, LengyelországTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Wojskowy Instytut Medyczny Panstwowy Instytut Badawczy
- Trial code
- EU 2024-516589-13-00
- Record updated
- 2026. július 20.
- Original description
The primary objective of the study is to evaluate the effect of metformin in reducing the rate of unplanned coronary revascularization in nondiabetic patients treated with percutaneous coronary angioplasty (PCI) for acute coronary syndrome.Read full original descriptionShow less
The primary objective of the study is to evaluate the effect of metformin in reducing the rate of unplanned coronary revascularization in nondiabetic patients treated with percutaneous coronary angioplasty (PCI) for acute coronary syndrome.
Inclusion: Age >18 years; First episode of the ACS in accordance with ESC (European Society of Cardiology) treating with percutaneous coronary intervention with drug-eluting stent implantation; Profession, place of residence (but close enough that it will not cause difficulty in monitoring during research); Uncomplicated course of the disease (ACS) as assessed by the treating physician; Patient negative history of diabetes; No hypoglycemic drugs before the admission or in the last 6 months; HbA1c< 6,5% (assessment during hospitalization); Written consent to participate in the study.
Exclusion: History of previous CABG; Significant valvular disease confirmed in ECHO; Known gastro-intestinal disease which could be potentially responsible for metformin intolerance (eg inflammatory bowel disease, GERD- gastro-esophageal reflux disease)- this criterion only for patients from "treatment group"; Known potential difficulties in collaboration with patients (dementia, mental disorders, distance from patients residence if considered as potentially problematic, alcoholism); Chronic kidney disease with GFR< 60 ml/min/1,73 m2 modo MDRD; ALT three times over UNL (upper normal limit) according to the laboratory criteria; Pregnancy and breast - breeding; Patient participation in another study; NYHA IV during hospitalization; Serious co-morbidity and estimated survival time of less than 2.5 years- as assessed by the treating physician; Hypersensivity to metformin.